Condition: Warm Antibody Autoimmune Hemolytic Anemia · Sponsor: Rigel Pharmaceuticals
The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| Arizona Oncology Associates, PC | Tucson, Arizona, United States | — |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| Loma Linda University Cancer Center | Loma Linda, California, United States | — |
| LAC/USC Health Center | Los Angeles, California, United States | — |
| University of California at San Francisco | San Francisco, California, United States | — |
| The Oncology Institute of Hope and Innovation | Whittier, California, United States | — |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | — |
| Mid-Florida Hematology & Oncology Centers, P.A. | Orange City, Florida, United States | — |
| Montgomery Cancer Center | Mount Sterling, Kentucky, United States | — |
| Johns Hopkins University School Of Medicine | Baltimore, Maryland, United States | — |
| Rcca Md Llc | Bethesda, Maryland, United States | — |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02612558